ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2386

Consensus Statement and Recommendations on Methotrexate Use in Combined Therapy with Biological or Targeted Synthetic Disease Modifying Drugs in Patients with Rheumatoid Arthritis

Jesus Tornero1, Mercedes Alperi-López 2, Ivan Castellvi 3, Juan José de Agustín de Oro 4, Alejandro Escudero 5, Rosario Garcia-Vicuña 6, Miguel Angel González-Gay 7, Cristina Hidalgo 8, Esteban Rubio 9, Raimon Sanmarti 10, Núria Casamira 11 and Jaime Calvo-Alen 12, 1Hospital de Guadalajara, Guadalajara, Spain, 2Hospital Universitario Central de Asturias, Oviedo, Spain, 3Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 4Hospital Universitari Vall d’Hebron, Barcelona, Spain, 5IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, 6Hospital Universitario de La Princesa, Madrid, Spain, 7Universidad de Cantabria and IDIVAL, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 8Hospital Clínico Universitario de Salamanca, Salamanca, Castilla y Leon, Spain, 9Rheumatology Department, University Hospital Virgen del Rocío, Sevilla, Spain, 10Department of Rheumatology, Hospital Clínic, Barcelona, Barcelona, Spain, 11Medical Department, Gebro Pharma S.A., Barcelona, Spain, 12Hospital Universitario Araba, Vitoria-Gasteiz, Spain

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Biologic agents and Janus kinase (JAK), methotrexate (MTX), recommendation, Rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 12, 2019

Title: RA – Treatments Poster III: Safety and Outcomes

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Our aim was to develop recommendations for the management of methotrexate (MTX) when considering the combination with biological (b) or targeted synthetic (ts) disease modifying drugs (DMARDs) in rheumatoid arthritis (RA).

Methods: Methodological procedures included nominal discussion group, systematic literature review, and Delphi survey for agreement. A panel of 11 expert rheumatologists, including two coordinators, was selected. The coordinators defined the goals, scope and users of the document and delivered a set of 11 relevant clinical questions regarding the use of MTX in combination with b or tsDMARDs, including the indication, dose, route of administration, dose-adjustments, efficacy and safety. To address them, an extensive systematic literature review was performed. The following PICO queries and inclusion criteria were defined, 1) RA patients (population); 2) on, or considering the start of combined therapy with MTX and b or tsDMARDs (intervention); reporting efficacy and/or safety variables like composite activity indexes, radiographic progression, serious adverse events, etc. (outcomes); 3) searches restricted to systematic literature reviews and meta-analysis, humans, English and Spanish articles. Then, an expert documentalist designed the search strategies (Medline, Embase and the Cochrane Library up to January 2019), using Mesh ant text word terms. Two reviewers selected the articles and collected data, independently. Subsequently, a manual search of the bibliography of the articles that were finally included was performed. Evidence tables were produced. The quality was evaluated with the Oxford Center for Evidence Based Medicine recommendations. Simultaneously, EULAR and ACR abstracts (2017 and 2018) were evaluated, along with national and international consensus and guidelines. This information was used by the coordinators to generate preliminary recommendations. Then, all the experts, in a nominal discussion group, agreed on the proposed objectives, scope and users, and analyzed the results of the review and preliminary recommendations. Recommendations were re-formulated as considered, and voted in a Delphi process (yes/no). Agreement was considered if at least 80% of experts voted yes. The level of evidence and grade or recommendation were assigned using the Oxford Centre for Evidence-Based Medicine guidance. The full document was critically appraised by the experts and the project was supervised at all steps by a methodologist.

Results: The systematic literature search retrieved 513 citations of which 61 were finally included. A total of 9 preliminary recommendations were proposed, 2 were not voted and were explained in the main text of the document, 3 new ones were proposed and 10 were finally voted and accepted (depicted in table 1 with their level of evidence, grade of recommendation and grade of agreement). The level of agreement was very high in all of them and was achieved in the first Delphi round.

Conclusion: This document is intended to help clinicians solve usual clinical questions and facilitate decision making when treating RA patients with MTX in combination with bDMARDs or tsDMARDs.


Figure 1

Firuge 1. Studies flow-chart.


Table 1

Table 1. Recommendations with their level of evidence -LE-, grade of recommendation -GR- and grade of agreement -GA-.


Disclosure: J. Tornero, None; M. Alperi-López, None; I. Castellvi, Actelion, 5, Boehringer -Ingelheim, 8, Gebro, 8, Kern, 5, Novartis, 8; J. de Agustín de Oro, None; A. Escudero, None; R. Garcia-Vicuña, None; M. González-Gay, AbbVie, 2, 5, 8, Abbvie, 2, 5, 8, Celgene, 5, 8, Eli Lilly, 2, 5, EliLilly, 2, 5, Jansen, 2, Janssen, 2, MSD, 2, 5, 8, Novartis, 2, 5, Pfizer, 5, 8, Roche, 2, 5, 8, Sanofi, 2, 5, 8, Sobi, 5, 8; C. Hidalgo, None; E. Rubio, Gebro, 2; R. Sanmarti, None; N. Casamira, Gebro, 3; J. Calvo-Alen, None.

To cite this abstract in AMA style:

Tornero J, Alperi-López M, Castellvi I, de Agustín de Oro J, Escudero A, Garcia-Vicuña R, González-Gay M, Hidalgo C, Rubio E, Sanmarti R, Casamira N, Calvo-Alen J. Consensus Statement and Recommendations on Methotrexate Use in Combined Therapy with Biological or Targeted Synthetic Disease Modifying Drugs in Patients with Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/consensus-statement-and-recommendations-on-methotrexate-use-in-combined-therapy-with-biological-or-targeted-synthetic-disease-modifying-drugs-in-patients-with-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/consensus-statement-and-recommendations-on-methotrexate-use-in-combined-therapy-with-biological-or-targeted-synthetic-disease-modifying-drugs-in-patients-with-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology